MedTrace Logo

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures

NCT02220387 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 352

Last updated 2015-10-06

No results posted yet for this study

Summary

The objective of this study is to investigate molecular, cytological and genetic features of occupational chronic obstructive pulmonary disease (COPD) in conditions of different occupational exposures. In order to achieve this goal serum pro-inflammatory cytokines and standard inflammation markers level, hemostasis, cytological analysis of bronchoalveolar lavage and associations of single nucleotide polymorphisms (SNPs) rs1800470 transforming growing factor β1 (TGF β1) gene, rs1828591 hedgehog interacting protein (HHIP) gene, rs4129267 interleukin 6 receptor (IL-6R) gene, rs1051730 nicotinic acetylcholine receptor 3 (CHRNA3) gene with COPD in subjects exposed to silica dust and in those exposed to polycyclic aromatic hydrocarbons exhaust will be investigated. The relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by C-reactive protein (hsCRP) and tumor necrosis factor-α (TNF α) serum concentration, in different occupational COPD groups will be studied. The hypothesis is that the mechanisms underlying disease development and progression are different due to environmental risk factor that reflex in differs in disease attributes - molecular biomarkers, cytology results and genetic susceptibility between COPD due to dust, COPD due to chemicals and COPD in smokers therefore COPD can be subdivided into ecological phenotypes according to environmental risk factor.

Conditions

Interventions

OTHER

exposure to respirable silica dust

History of exposure to respirable silica dust due to job

OTHER

exposure to polycyclic aromatic hydrocarbons exhaust

history of exposure to polycyclic aromatic hydrocarbons exhaust due to job

Sponsors & Collaborators

  • Siberian Branch of the Russian Academy of Medical Sciences

    collaborator OTHER

  • Novosibirsk City Hospital #2

    lead OTHER

Principal Investigators

  • Liubov Shpagina, PhD · Novosibirsk Citi Hospital #2, Novosibirsk State Medical University

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02220387 on ClinicalTrials.gov